Is ImClone Out of the Woods?

Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth

Click here for reuse options!
Copyright 2004 Biotechblog

Leave a Reply

%d bloggers like this: